Your browser is no longer supported. Please, upgrade your browser.
Sigilon Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.12 Insider Own6.30% Shs Outstand31.57M Perf Week6.63%
Market Cap201.02M Forward P/E- EPS next Y-2.68 Insider Trans-8.80% Shs Float25.05M Perf Month27.29%
Income-67.80M PEG- EPS next Q-0.71 Inst Own61.20% Short Float3.30% Perf Quarter-41.64%
Sales13.60M P/S14.78 EPS this Y-19.30% Inst Trans-0.66% Short Ratio3.03 Perf Half Y-70.57%
Book/sh3.52 P/B1.74 EPS next Y1.10% ROA-39.20% Target Price- Perf Year-
Cash/sh4.94 P/C1.24 EPS next 5Y- ROE-99.90% 52W Range4.33 - 54.32 Perf YTD-87.28%
Dividend- P/FCF- EPS past 5Y- ROI-31.90% 52W High-88.75% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low41.11% ATR0.51
Employees99 Current Ratio3.70 Sales Q/Q-50.00% Oper. Margin- RSI (14)55.38 Volatility8.57% 9.41%
OptionableYes Debt/Eq0.00 EPS Q/Q25.50% Profit Margin- Rel Volume3.78 Prev Close6.08
ShortableYes LT Debt/Eq0.18 EarningsAug 10 BMO Payout- Avg Volume272.85K Price6.11
Recom1.70 SMA208.51% SMA508.65% SMA200-67.48% Volume1,031,066 Change0.49%
Aug-02-21Resumed Jefferies Buy $15
Dec-29-20Initiated Morgan Stanley Equal-Weight $45
Dec-29-20Initiated Jefferies Buy $60
Dec-29-20Initiated Barclays Overweight $48
Sep-09-21 07:00AM  
Sep-02-21 07:00AM  
Aug-10-21 07:00AM  
Jul-23-21 07:00AM  
Jul-19-21 07:00AM  
Jul-14-21 03:21PM  
Jul-12-21 12:36PM  
Jul-09-21 01:59PM  
Jun-16-21 07:00AM  
Jun-14-21 04:05PM  
Jun-02-21 06:23AM  
May-27-21 07:00AM  
May-25-21 06:00AM  
May-19-21 09:01AM  
May-10-21 04:05PM  
May-06-21 07:00AM  
Apr-27-21 04:30PM  
Apr-08-21 07:00AM  
Mar-30-21 09:30AM  
Mar-18-21 04:05PM  
Mar-08-21 06:36AM  
Mar-05-21 07:00AM  
Mar-04-21 07:00AM  
Feb-08-21 08:00AM  
Jan-13-21 07:00AM  
Dec-29-20 10:12AM  
Dec-17-20 07:00AM  
Dec-08-20 05:00PM  
Dec-04-20 03:15PM  
Dec-03-20 09:02PM  
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDERSON DANIEL GRIFFITHDirectorJun 02Sale10.00200,0002,000,0002,022,222Jun 04 04:15 PM
ELI LILLY & Co10% OwnerDec 08Buy18.00300,0005,400,0002,744,443Dec 10 05:00 PM